US5419904A - Human B-lymphoblastoid cell line secreting anti-ganglioside antibody - Google Patents

Human B-lymphoblastoid cell line secreting anti-ganglioside antibody Download PDF

Info

Publication number
US5419904A
US5419904A US08/026,320 US2632093A US5419904A US 5419904 A US5419904 A US 5419904A US 2632093 A US2632093 A US 2632093A US 5419904 A US5419904 A US 5419904A
Authority
US
United States
Prior art keywords
antibody
human
cell line
melanoma
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/026,320
Other languages
English (en)
Inventor
Reiko F. Irie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/026,320 priority Critical patent/US5419904A/en
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Priority to AU62380/94A priority patent/AU687791B2/en
Priority to ES94909585T priority patent/ES2211877T3/es
Priority to DE69433378T priority patent/DE69433378T2/de
Priority to PCT/US1994/001469 priority patent/WO1994019457A1/en
Priority to CA002156857A priority patent/CA2156857C/en
Priority to DK94909585T priority patent/DK0687295T3/da
Priority to PT94909585T priority patent/PT687295E/pt
Priority to JP51902794A priority patent/JP4796682B2/ja
Priority to EP94909585A priority patent/EP0687295B1/en
Priority to AT94909585T priority patent/ATE255633T1/de
Application granted granted Critical
Publication of US5419904A publication Critical patent/US5419904A/en
Priority to JP2011109904A priority patent/JP2011209287A/ja
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF CALIFORNIA
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates generally to Epstein-Barr virus-transformed human B-lymphoblastoid cell lines. More particularly, the present invention relates to such cell lines which are capable of producing antibodies which can be used to directly treat tumors or which can be used to raise anti-id antibodies for use as surrogate antigens or diagnostic reagents.
  • variable regions of immunoglobulins could act as external antigens.
  • recognition of idiotypes on the antigen-combining site, or on the framework of AB1 results in the production of anti-idiotypes (anti-ids or AB2) beta and alpha, respectively.
  • anti-idiotypes anti-ids or AB2
  • Such "internal image" anti-idiotypes by virtue of their complementarity with the original antigen binding site, mimic the original antigen and often behave in a similar biological manner.
  • the concept of internal image refers to the fact that some AB2 molecules can act as surrogate antigens and their administration can lead to the production of anti-anti-idiotype antibodies displaying similar characteristics of AB1.
  • anti-ids as surrogate antigens has generated much interest among researchers, many of whom have experimented with AB2 vaccines for active specific immunization against viruses, bacteria, and other pathogens (2,3). This approach is useful when a conventional vaccine or antibodies are not available, or are difficult to produce or when the corresponding antigen is not a suitable product for genetic engineering.
  • anti-ids can be used as immunomodulators for up-regulating immunity against cancer, and as immunosuppressants to prevent rejection of transplanted organs and to prevent the progression of auto-immune disease.
  • Gangliosides are glycospingolipids that are fundamental membrane components on human tissues. Gangliosides undergo characteristic changes during malignant transformation of normal cells and thus are desirable target antigens for immunotherapy of cancer. Melanoma synthesizes a large number of gangliosides and thus has served as a useful model to assess the potential of gangliosides as immunotherapy targets. A number of tumor-associated gangliosides of human melanoma and their respective immonogenicity have been defined (12-29). In addition, a number of studies have shown that active immunization with ganglioside antigens results in prolonged survival of melanoma patients (4,5). Nevertheless, this technique suffers in many areas, namely that the ganglioside antigen are many times rare or in short supply.
  • Tumor-associated antigens in most cases, are present in nature only at low levels and are relatively difficult to purify in large amounts. In contrast, anti-ids can be secreted from hybridoma cells at low cost over long periods of time. Furthermore, current genetic engineering technology, while not applicable to ganglioside epitopes, can be used to synthesize the anti-id peptides. Anti-ids previously developed for active specific immunotherapy of human cancer have used murine monoclonal antibodies (MuMabs) as the immunogens (6-11).
  • Murine monoclonal antibodies have also been employed to define and characterize many antigenic molecules on human cancer cells.
  • Murine monoclonal antibodies have several advantages over human monoclonal antibodies including a strong affinity for tumor antigens, higher antibody secretion by hybridoma ascites, and high antigen density on tumor cells.
  • human monoclonal antibodies HuMAbs
  • HuMAbs human monoclonal antibodies
  • HuMAbs may be preferable since repeated injections of MuMAbs induce anti-murine Ig antibodies in virtually all patients. This leads to formation of immune complexes and immune reactions with potentially hazardous complications.
  • HuMAbs may recognize epitopes that are overlooked by the murine immune system.
  • HuMAbs that react with ganglioside antigens on human cancer cells and the demonstration of their anti-tumor effect at the clinical level has been reported (23,12).
  • Patients with recurrent melanoma received intratumor injections of HuMAb to ganglioside GD2 or GM2, and partial or complete regression was observed in about 70% of the patients.
  • the target antigen GD2 or GM2 was not expressed on the tumor cells.
  • Two HuMAbs identified as L55 and L72 have been produced from human B-lymphoblastoid cell lines which have been transformed by Epstein-Barr virus (29). The L55 and L72 antibodies were both found to be reactive with a variety of tumor cells.
  • immunological assays which have been used to detect the quality and quantity of gangliosides present on a given tumor. They include: the immune adherence assay (IA); direct immunofluorescence with fluorescinated microspheres; and IA absorption, and a biochemical assay. These assays each have certain limitations and advantages.
  • the immunologic assay requires single cell suspensions from the biopsied tumor tissues. However, it is often difficult to obtain viable high yield tumor cell populations. Also, under a light microscope, tumor cells may not be readily distinguished from monocytes and macrophages.
  • the biochemical assay does not require intact cells. However, a relatively large volume of tumor is necessary for ganglioside extraction and measurement of sialic acid in the glycolipid preparation.
  • the most commonly utilized immunologic technique for defining antigen expression on biopsy specimens using murine monoclonal antibodies is immunohistochemical staining of tissue sections.
  • this sensitive method is not readily applicable to combinations of human monoclonal antibodies and human tissues.
  • the indirect staining of human tumor tissues with the second antibody (anti-human Ig) usually results in high background from non-specific binding to abundant endogenous human Ig.
  • Direct immunostaining using biotinylated human monoclonal antibodies may overcome this high background (30).
  • this method is usually less sensitive and is most effective when a high density antigen is present on the cell surface.
  • the anti-ganglioside antibodies produced by the new cell lines will be useful in direct treatment of tumors and also in the production of anti-ids for use as surrogate antigens or diagnostic reagents.
  • a human B-lymphoblastoid cell line has been developed which secretes anti-ganglioside antibody which is reactive with a variety of tumors and which has been demonstrated to be effective in treating melanoma.
  • the cell line of the present invention is identified as L612 and is maintained at the Division of Surgical Oncology at the University of California at Los Angeles School of Medicine.
  • the L612 cell line was deposited on Apr. 4, 1991 at the American Type Culture Collection (Rockville, Md.) under ATCC accession number CRL 10724.
  • the L612 cell line is used to produce an IgM kappa antibody which is reactive with tumor antigen.
  • the L612 antibody has been shown to be effective in treating melanoma tumors when administered by intralesional injection.
  • the L612 antibody is used to prepare murine anti-id monoclonal antibodies which are useful as surrogate antigens or which can be used in diagnostic procedures.
  • FIG. 1 is the nucleotide/amino acid sequence for the variable region of the L612 antibody heavy chain.
  • the complementary determining regions are underlined.
  • FIG. 2 is the nucleotide/amino acid sequence for the variable region of the L612 antibody light chain.
  • the complementary determining regions are underlined.
  • the cell line in accordance with the present invention is a B-lymphoblastoid cell line which has been transformed by the Epstein-Barr virus transformation technique.
  • the cell line is identified as L612 and is maintained at the Division of Surgical Oncology at the University of California at Los Angeles School of Medicine.
  • the L612 cell line was deposited on Apr. 4, 1991 at the American Type Culture Collection (12301 Parklawn Drive, Rockville, Md. 20852-1776) under ATCC accession number CRL 10724.
  • the L612 cell line was established in culture from lymphocytes by the same Epstein-Barr virus transformation technique which was used to produce two other human monoclonal anti-ganglioside antibodies, L55 (anti-GM2) and L72 (anti-GD2) (26-27 and 29). The same transformation procedure as set forth in detail in reference (29) was followed in establishing the L612 cell line.
  • the Epstein-Barr virus transformation technique used to establish the prior L55 and L72 cell lines, as well as the present L612 cell line, is a conventional procedure which is known and used by researchers in this field.
  • HBSS Hank's balanced salt solution
  • the E-rosette formation technique was used to remove T-lymphocytes, and the B-lymphocyte fraction was washed with HBSS three times and then were incubated with Epstein-Barr virus (EBV) for 20 hours in RPMI 1640 containing 10% fetal calf serum.
  • EBV Epstein-Barr virus
  • a human breast cancer cell line, MDA-MB 436 (31) and a human melanoma cell line, UCLA-SO-M12 (32) were used as targets. While clones secreting antibodies positive to 436 breast cancer cell line ceased to produce antibodies very soon after establishment, those reacting to the M12 melanoma cell line continued to produce antibody and were stable. Clones secreting antibodies were adapted to RPMI 1640 containing a lower concentration of fetal calf serum gradually. The clones were then recloned 7 times in serum free medium containing growth factor (FDA approved HB series serum free medium obtained from Irvine Scientific Co.) (Irvine, Calif.). Doubling time of L612 cell line is less than one day.
  • the cell line secretes greater than 20 ⁇ g/ml IgM kappa monoclonal antibody.
  • the L612 antibody in the spent medium was purified as previously described (25).
  • the antibody produced by the L612 cell line is isolated according to any of the conventional procedures used to remove and purify antibodies from cell cultures.
  • the purified L612 antibody was tested for reactivity with a variety of human tumor tissues.
  • the L612 antibody has a strong cytotoxic activity to antigen positive human tumor cells in the presence of complement.
  • the reactivity was tested using both the immune adherence (IA) and immune adherence absorption (IAA) assays. The results are summarized in TABLE I.
  • the reactivity of the L612 antibody with various authentic glycolipids was also determined.
  • the glycolipids and their respective antigen titer with respect to L612 antibody are listed in Table II.
  • the authentic glycolipids (5 nmol), were tested for L612 antigen activity by the IA inhibition test.
  • Three gangliosides, GM 4 , GM 3 and PSG showed positive reactivity; however, two of these, GM 4 and GM 3 showed stronger binding (1:64) than SPG (1:16).
  • gangliosides including II 3 NeuGc-Lac-Cer, IV 3 NeuGc-nLcOse 4 -Cer, GM 2 , GM 1a , GD 3 , GD 2 , GD 1a , GD 1b and GT 1b , and neutral glycolipids including GbOse 3 -Cer, GbOse 4 -Cer and GgOse 4 -Cer showed no antigenic activity.
  • ELISA and enzyme immunostaining on TLC plates with authentic glycolipids were performed. The results obtained by ELISA and enzyme immunostaining were similar to those of the IA inhibition assay.
  • the ELISA was performed using 15 authentic glycolipids bound to microtiter wells. Again, the three gangliosides, GM 3 , GM 4 and SPG showed clear binding activity on solid phase ELISA. None of the remaining glycolipids showed reactivity.
  • HuMab L612 Immunostaining of frozen sections with HuMab L612 indicated a strong specificity for neoplastic tissue, including melanoma, colon adenocarcinomas and lung adenocarcinomas.
  • HuMab provides an excellent marker for identifying certain types of neoplastic tissues. It has been shown that HuMab L6 12 binds to renal cell carcinomas (35).
  • RNA sequence of the variable regions for both the light and heavy chains of the L612 antibody were determined by polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • the guanidium thiocyanate/cesium chloride procedure was used to prepare total RNA from the L612 B lymphoblast line (34).
  • Ten ⁇ g of RNA was mixed with 60 pmol of either mu heavy or kappa light chain 3' primers and heated at 70° C. for 10 min.
  • the mixture was then added to 50 ⁇ l reverse transcriptase reaction solution containing 10 ⁇ l 5X reverse transcriptase buffer (BRL), 4 ⁇ l 10 mM dNTP mix (200 ⁇ M of dATP, dCTP, dGTP, and dTTP final concentration) and 3 ⁇ l 600 units reverse transcriptase (Superscript, BRL).
  • BRL reverse transcriptase buffer
  • the mixture was incubated at 37° C. for 1 hour.
  • PCR reaction was then performed with: 97 ⁇ l of PCR mixture was added to 3 ⁇ l of RNA-cDNA mixture.
  • the PCR mixture contained 10X pCR buffer (Perkin Elmer, Calif.), 10 mM dNTPs mix at 60 ⁇ M final concentration of each dNTP, 5 units of Taq polymerase (Perkin Elmer), and 60 ⁇ M appropriate 5' and 3' heavy and light chain primers.
  • the mixtures were subjected to 35 cycles of amplification at 91° C. for 1 in., 52° C. for 2 min., and 72° C. for 1.5 min. followed by a final incubation at 72° C. for 10 min. in a Perkin Elmer/Cetus thermal cycler.
  • the gel products were isolated, pooled, subjected to phenol/chloroform extraction and ethanol precipitation.
  • the DNA was then digested with appropriate restriction enzymes, extracted, precipitated and purified with GeneClean (Bio101, CA).
  • the DNA was ligated into appropriate cut restriction sites of Bluescript vector (Stratagene, Calif.).
  • Ten independent clones of the variable region mu chain and four independent clones of the variable region kappa chain were isolated and sequenced.
  • a J H heavy chain probe was used for screening and verifying the heavy chain clones. Sequencing was done by the dideoxynucleotide method with T7 DNA polymerase (Sequenase, USB, Cleveland, Ohio) according to the manufacturer's protocol.
  • the primers used were as follows. Heavy mu chain leader primers (3 primers) (29):
  • Heavy mu chain J region primer was CCAAGCTTAGACGAGGGGGAAAAGGGTT Sequence No. 8. This contains an Hind III site (underlined).
  • Light kappa chain leader primers were as follows (2 primers)(30). GACATCGAGCTCACCCAGTCTCCA Sequence No. 9; and GAAAT TGAGCTCACGAGTCTCCA Sequence No. 10. These primers contain an Sac I site (underlined).
  • the light kappa chain J region primer was GCGCCGTCTAGAACTAACACTCTCCCCTGTTGAAGCTCTTTGTGACGGGCAAG Sequence No. 11. This primer contains an Xba site (underlined).
  • the cloned cDNA nucleotide sequence and the encoded amino acid sequence for the variable region of the heavy chain is set forth in SEQ ID NO:1.
  • the heavy chain variable region amino acid sequence above is set forth in SEQ ID NO: 2.
  • the cloned cDNA nucleotide sequence and the encoded amino acid sequence for the variable region of the light chain is set forth in SEQ ID NO:3.
  • the light chain variable region amino acid sequence above is set forth in SEQ ID NO:4.
  • the nucleotide/amino acid sequence for the heavy chain variable region is also shown in FIG. 1.
  • the complimentary determining regions (CDR's) 1, 2 and 3 are underlined.
  • the nucleotide/amino acid sequence for the light chain variable region is also shown in FIG. 2.
  • the CDR's 1, 2 and 3 are also underlined.
  • the L612 antibody in accordance with the present invention is administered to patients for treating tumors which contain the GM3 ganglioside or NeuAc2-3 Galactose epitope.
  • the GM3 ganglioside includes a terminal sugar having a Neu ⁇ 2-3 Galactose residue.
  • Any of the conventional procedures used for administering antibodies to patients for treating such tissues may be used. These procedures include intravenous or intraperitoneally injection and intralesional injection. Intralesional injection is a preferred method of administration for cutaneous recurrent tumors.
  • the L612 antibody and the antibody producing cell line can be modified or altered by known procedures to form other immunoglobulin isotypes and cells producing such which may efficiently bind and kill tumor cells (33).
  • the particular dosage used will vary depending upon tumor antigenicity and can be determined according to known procedures for administering antibodies such as L55 and L72.
  • the L612 monoclonal antibody reacts strongly with human melanoma tumor biopsies.
  • the L612 antibody also reacts less strongly with human tumor biopsies from lung cancer, breast cancer, pancreatic cancer, colon cancer and kidney cancer.
  • the UCLASO-M12 melanoma cell line was identified as the most reactive cell line among the lines tested with the L612 monoclonal antibody.
  • the UCLASO-M12 cell line is maintained at the Division of Surgical Oncology at the University of California at Los Angeles School of Medicine.
  • HuMab L612 HuMab was used as therapeutic agent for the treatment of cutaneous malignant melanoma.
  • HuMab L612 was purified for human use as previously described (25). It was demonstrated in previous studies that intralesional injection of human anti-G D2 HuMab L72 could induce regression of cutaneous melanoma (23). In the present example the effect of HuMab L612 and HuMab L72 is compared.
  • the L612 antibody is also useful in producing hybridomas which in turn can be used to produce anti-ids for use as surrogate antigens or diagnostic reagents.
  • the production of hybridomas and subsequent generation of anti-ids are described in the following exemplary procedure:
  • mice were immunized by a subcutaneous injection of 200 ⁇ g of purified L612 monoclonal antibody in complete Freund's adjuvant. After 2 weeks the animals were boosted by another subcutaneous injection of L612 in incomplete Freund's adjuvant. Eleven days following the booster, the mice were injected intraperitoneally with 200 ⁇ g of L612 in saline. After three days the spleens were removed and the splenocytes fused with myeloma cell line SP2/O using the standard procedure to produce hybridomas.
  • Hybridomas secreting anti-ids were identified by their strong binding reactivity to HuMAb L612 and absent reactivity to three other control human IgMs: L55, L72, and human serum IgM. Unrelated proteins used as antigens included fetal bovine serum and human serum albumin. 50 ⁇ l of IgMs or proteins (50 ⁇ g/ml) were coated on a 96-well ELISA plate and served as antigens to detect AB2. Peroxidase-conjugated goat anti-mouse IgG+IgM was used as the AB2 detection probe followed by substrate and reading absorbency at 490 nm as described previously (19).
  • these anti-L612 antibodies were AB2 beta-type directed against the antigen combining site of L612, or were AB2 alpha antibodies bound to peptide regions outside the antigen-combining site of L612, the inhibitory activity of these anti-L612 antibodies against L612 binding to GM3 positive target cell lines or to the purified antigen, ganglioside GM3, was tested by using three assay systems: IA inhibition, cell-ELISA inhibition, and GM3-ELISA inhibition. Of the 40 antibodies tested, seven inhibited L612 binding to an antigen positive target melanoma cell line, (UCLASO-M12), and to GM3 greater than 50% in the assays, while 12 others had weak or no inhibitory activity.
  • inhibitory anti-ids Of the seven inhibitory anti-ids, one identified as 4C10 was selected for cloning as the preferred beta-type anti-id for use in treating tumors. From the non-inhibitory group the anti-id identified as 18C6 was selected for cloning as the preferred alpha-type anti-id for use in immunodiagnostic assays. Both anti-ids, 4C10 and 18C6, were tested with isotype antiglobulins and found to be of the IgG1 class and contain kappa light chains.
  • the 4C10 and 18C6 cloned hybridoma cell lines were grown in FCS-containing RP MI 1640 medium and secreted 5-10 ⁇ g/ml of antibody into culture supernatants. Titers of the anti-ids in these culture supernatants against L612 by ELISA ranged between 1:200 to 1:1000/10 6 hybridoma.
  • Anti-id 18C6 demonstrated low binding inhibition of HuMAb L612 to target cells in the IA assay and to ganglioside GM3 in ELISA whereas 4C10 at the same antibody concentration showed strong inhibition in both the ELISA assay and the IA assay.
  • 4C10 and 18C6 failed to inhibit the binding of an unrelated antigen system, HuMAb L72, to M14 target cells, or to GD2 antigen.
  • the lack of binding inhibition of 18C6 indicates a binding location on L612 antibody outside the GM3 antigen combining site, and the specific binding inhibition of 4C10 indicates its binding location to be within or near the antigen combining site.
  • hybridoma cell lines which secrete the 4C10 and 18C6 monoclonal anti-ids are being maintained at the Division of Surgical Oncology at the University of California at Los Angeles School of Medicine.
  • the 4C10 anti-id and other beta-type anti-ids raised against L612 can be used alone or in combination with other agents to treat tumors. They are preferred for use in treating melanoma tumors. These beta-type anti-ids may also be used as an immunomodulator to enhance anti-cancer immunity, suppress organ transplant rejection and suppress autoimmune disease.
  • the beta-anti-ids may be administered by any of the conventional procedures used to introduce antibodies into patients. These procedures include subcutaneous, intravenous or intratumor injection.
  • the beta-type anti-ids are preferably conjugated with KLH and emulsified in a suitable carrier such as Freund's complete adjuvant.
  • suitable carrier such as Freund's complete adjuvant.
  • the particular doses used for the beta-type anti-ids will vary depending upon the tumor being treated and numerous other factors.
  • the dosage levels are established by the known techniques and principles generally recognized and utilized in treating patients with antigen immunization agents or monoclonal antibodies.
  • mice Five syngeneic Balb/c mice were immunized with purified 4C10-KLH. As controls, four mice were immunized with mouse IgG1-KLH and one mouse with KLH alone. The immunized sera were monitored by ELISA using purified GM3 as the antigen source and by the IA assay using the antigen positive M12 melanoma cell line. In the ELISA, peroxidase conjugated goat anti-mouse IgM+IgG (Boeringer Mannheim) was used as a second antibody.
  • Measurable antibody was produced in three of the five immunizations with 100 ⁇ g 4C10-KLH.
  • the immunized sera bound to GM3 but not to CDH (asialo-GM3).
  • Sera from the five mice immunized with IgG-KLH or KLH alone gave no response to either glycolipid.
  • the majority of the reactivity was identified as IgM.
  • the immunized murine sera were pre-absorbed by human red blood cells at 4° C. overnight. An IA score of 4+ was obtained at 1:10 dilution of the absorbed sera. Control sera gave no reactivity even at 1:2 dilution.
  • IA inhibition was performed using GM3 (10 ⁇ g), CDH (10 ⁇ g), 4C10 (10 ⁇ g) and unrelated IgG1 (10 ⁇ g) purified from Balb/c hybridoma ascites. While reactivity was completely inhibited by GM3 or purified 4C10, no inhibition was obtained with CDH or unrelated IgG1.
  • beta-type anti-ids produce AB3 anti-bodies which are immunoreactive with melanoma tumors. Accordingly, these beta-type anti-ids which are raised in response to the L612 antibody are effective as an immunization agent in the treatment of melanoma.
  • the alpha-type anti-ids produced in response to the L612 antibody may be used immunodiagnostic procedures such as a three-step cell-ELISA procedure and a three step immunoperoxidase staining of tumor tissue sections. Examples of practice are as follows:
  • Viable M12 cells (1 ⁇ 10 5 ) were plated onto a U-bottom 960 well microtiter plate (Immulon-1, Dynatec) after pre-blocking with 1% BSA-PBS. 50 ul of L612 (100 ⁇ g/ml) were added and incubated for 1 hour at room temperature. After washing the mixture to remove unbound HuMAb L612, the cells were incubated with murine monoclonal anti-id 18C6 (100 ⁇ g/ml) for 1 hour at room temperature. After washing, 50 ⁇ l of peroxidase-conjugated goat anti-mouse IgG antibody (1/10,000 diluted) (Jackson Immuno Research) were added and the plate was incubated for 30 minutes. After washing with PBS solution, the substrate for peroxidase was added and binding activity was determined as a function of absorbance at 490 nm with a V max kinetic microplate reader.
  • L612 100 ⁇ g/ml
  • the cell bound HuMAb L612 should have reduced its binding activity to anti-id beta, yet still retain full binding activity to anti-id alpha.
  • the above-described procedure confirmed this process using cultured M12 melanoma cells which express a high density of the corresponding antigen.
  • the above-described cell binding assay represents a modified form of the ELISA technique.
  • Control anti-ganglioside HuMAbs included L55 (IgManti-GM2) and L72 (IgM anti-GD2), both of which exhibit strong binding ability to the GM2 and GD2 rich M14 melanoma cell line (26, 27).
  • the anti-id 186C6 reacted strongly to M12 cells after pre-incubation with HuMaB L612, but did not react to M14 cells that were pre-incubated with L55 or L72 HuMAb.
  • the peroxidase-conjugated anti-mouse Ig also failed to react with M12 cells in other controls including murine anti-id alone, L612, or L612 plus (anti-id beta).
  • the cell-ELISA assay was then applied to several other human tumor cell lines.
  • a two-step cell binding assay (HuMAb+peroxidase-conjugated anti-human IgM) was compared with the three-step cell-binding assay to evaluate the validity of the three-step assay.
  • the three-step assay had parallel reactivity with the two-step assay and was slightly more sensitive in almost every cell line. This data indicates that the ELISA absorbency value of the three-step assay accurately reflects differences in the density of cell surface GM3 antigens and correlates closely with the two-step in vitro assays.
  • Tissue sections 4 ⁇ m thick were cut from tissues freshly frozen in OTC compound and immediately fixed in cold formaldehyde buffer (12 g Tris buffer, 9 g sodium chloride, 40 ml 37% formaldehyde, pH 7.4) and air dried. Slides were dipped in Tris buffer for five minutes then treated with 3% hydrogen peroxide for 10 minutes to quench endogenous peroxidase activity.
  • HuMAb L612 (10 ⁇ g IgM in 200 ⁇ l) was then applied and incubated for 45 minutes.
  • the slides were washed in Tris buffer for 5 minutes, the purified anti-id 18C6 (10 ⁇ g IgG1 in 200 ul) was applied and incubated for 30 minutes.
  • the slides were washed once more in tap water, counterstained with hematoxylin, and cover-slips applied to the stained sections using glycerol-gelatin.
  • the immunoperoxidase three-step assay was applied successfully to detect binding of L612 antibody to surgically biopsied tumor tissues that had been snap frozen.
  • the L612 antibody may be used to make chimeric antibodies which are also useful in a variety of treatments or as diagnostic reagents. Accordingly, the present invention is not limited to the specific embodiments as illustrated herein, but is only limited by the following claims.
  • Ganglioside GM2 on the K56 cell line is recognized as a target structure by human natural killer cells. Int J Cancer 40: 12-17, 1987.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US08/026,320 1990-11-05 1993-02-26 Human B-lymphoblastoid cell line secreting anti-ganglioside antibody Expired - Lifetime US5419904A (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
US08/026,320 US5419904A (en) 1990-11-05 1993-02-26 Human B-lymphoblastoid cell line secreting anti-ganglioside antibody
JP51902794A JP4796682B2 (ja) 1993-02-26 1994-02-09 抗ガングリオシド抗体を産生するヒトのｂリンパ芽腫細胞系
DE69433378T DE69433378T2 (de) 1993-02-26 1994-02-09 Humane b-lymphoblastoiden zellinie welche anti-gangliosid-antikörper sekretiert
PCT/US1994/001469 WO1994019457A1 (en) 1993-02-26 1994-02-09 Human b-lymphoblastoid cell line secreting anti-ganglioside antibody
CA002156857A CA2156857C (en) 1993-02-26 1994-02-09 Human b-lymphoblastoid cell line secreting anti-ganglioside antibody
DK94909585T DK0687295T3 (da) 1993-02-26 1994-02-09 Human B-lymfoblastoidcellelinje, der secernerer anti-gangliosid-antistof
AU62380/94A AU687791B2 (en) 1993-02-26 1994-02-09 Human B-lymphoblastoid cell line secreting anti-ganglioside antibody
ES94909585T ES2211877T3 (es) 1993-02-26 1994-02-09 Linea celular linfoblastoide b humana que secreta un anticuerpo anti-gangliosido.
EP94909585A EP0687295B1 (en) 1993-02-26 1994-02-09 Human b-lymphoblastoid cell line secreting anti-ganglioside antibody
AT94909585T ATE255633T1 (de) 1993-02-26 1994-02-09 Humane b-lymphoblastoiden zellinie welche anti- gangliosid-antikörper sekretiert
PT94909585T PT687295E (pt) 1993-02-26 1994-02-09 Linhagem celular b-linfoblastoide humana que segrega anticorpos anti-gangliosidos
JP2011109904A JP2011209287A (ja) 1993-02-26 2011-05-16 ヒトｂリンパ芽腫細胞系から分泌される抗ガングリオシド抗体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60980390A 1990-11-05 1990-11-05
US08/026,320 US5419904A (en) 1990-11-05 1993-02-26 Human B-lymphoblastoid cell line secreting anti-ganglioside antibody

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US60980390A Continuation-In-Part 1990-11-05 1990-11-05

Publications (1)

Publication Number Publication Date
US5419904A true US5419904A (en) 1995-05-30

Family

ID=21831157

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/026,320 Expired - Lifetime US5419904A (en) 1990-11-05 1993-02-26 Human B-lymphoblastoid cell line secreting anti-ganglioside antibody

Country Status (11)

Country Link
US (1) US5419904A (da)
EP (1) EP0687295B1 (da)
JP (2) JP4796682B2 (da)
AT (1) ATE255633T1 (da)
AU (1) AU687791B2 (da)
CA (1) CA2156857C (da)
DE (1) DE69433378T2 (da)
DK (1) DK0687295T3 (da)
ES (1) ES2211877T3 (da)
PT (1) PT687295E (da)
WO (1) WO1994019457A1 (da)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837845A (en) * 1991-06-28 1998-11-17 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US5854069A (en) * 1996-04-22 1998-12-29 The Wistar Institute Of Anatomy & Biology GD2 anti-idiotypic antibodies and uses thereof
US6491914B1 (en) * 1993-12-09 2002-12-10 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions including the anti-idiotypic monoclonal antibodies
US6573055B2 (en) * 1997-04-21 2003-06-03 Glycozyme, Inc. Determination of recombinant glycosylated proteins and peptides in biological fluids
US20030158389A1 (en) * 1998-04-02 2003-08-21 Genentech, Inc. Polypeptide variants
US20030166868A1 (en) * 1998-04-02 2003-09-04 Genentech, Inc. Polypeptide variants
US20040191244A1 (en) * 1999-01-15 2004-09-30 Genentech, Inc. Polypeptide variants with altered effector function
US20040248224A1 (en) * 2000-05-18 2004-12-09 Alving Carl R. Detection of antibodies to squalene in serum
US20050080239A1 (en) * 2001-04-06 2005-04-14 The Scripps Research Institute Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
US20060160160A1 (en) * 2000-05-18 2006-07-20 Alving Carl R Detection of human antibodies to squalene in serum
US20060194291A1 (en) * 1999-01-15 2006-08-31 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US20100008851A1 (en) * 2008-06-30 2010-01-14 Morphotek Inc, Anti-gd2 antibodies and methods and uses related thereto
US20100255013A1 (en) * 2001-10-25 2010-10-07 Presta Leonard G Glycoprotein compositions
US8969526B2 (en) 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US12503503B2 (en) 2018-10-29 2025-12-23 Hoffmann-La Roche Inc. Bispecific anti-VEGF/ANG2 antibody formulation

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU669379B2 (en) * 1992-09-07 1996-06-06 Kyowa Hakko Kirin Co., Ltd. Humanized antibodies
WO1999043815A2 (en) * 1998-02-27 1999-09-02 Novopharm Biotech Inc. Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof
TW200510532A (en) * 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
JP4762717B2 (ja) 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
CA2888652C (en) 2012-11-30 2020-09-22 Katinger Gmbh Recombinant human igm-antibody effective against cancer cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5208146A (en) * 1990-11-05 1993-05-04 The Regents Of The University Of California Murine monoclonal anti-idiotype antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4107154A1 (de) * 1990-10-11 1992-04-16 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen melanom
EP0492409A1 (en) * 1990-12-18 1992-07-01 Ishihara Sangyo Kaisha, Ltd. Human monoclonal antibody
WO1993010221A1 (en) * 1991-11-13 1993-05-27 The Regents Of The University Of California Chimeric murine/human anti-idiotype monoclonal antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5208146A (en) * 1990-11-05 1993-05-04 The Regents Of The University Of California Murine monoclonal anti-idiotype antibodies

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Furukawa, et al., J. Biol Chem 263(34):18507 18512, 1988. *
Furukawa, et al., J. Biol Chem 263(34):18507-18512, 1988.
Harris, W. J. et al., TIBTECH, 11:42 44, Feb. 1993. *
Harris, W. J. et al., TIBTECH, 11:42-44, Feb. 1993.
Hellstrom, I et al., Accomplishments in Cancer Res., pp. 216 240, 1984. *
Hellstrom, I et al., Accomplishments in Cancer Res., pp. 216-240, 1984.
Matsuki, T., et al., Proc. Ann Meeting Am Assoc Cancer Res, 29:A1694, 1988. *
Morrison, S. L., et al, PNAS, 81:6851 6855, Nov. 1984. *
Morrison, S. L., et al, PNAS, 81:6851-6855, Nov. 1984.
Waldmann, T. A., Science, 252:1657 1662, Jun. 1991. *
Waldmann, T. A., Science, 252:1657-1662, Jun. 1991.

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990297A (en) * 1991-06-28 1999-11-23 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US5837845A (en) * 1991-06-28 1998-11-17 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US6491914B1 (en) * 1993-12-09 2002-12-10 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions including the anti-idiotypic monoclonal antibodies
US5854069A (en) * 1996-04-22 1998-12-29 The Wistar Institute Of Anatomy & Biology GD2 anti-idiotypic antibodies and uses thereof
US6573055B2 (en) * 1997-04-21 2003-06-03 Glycozyme, Inc. Determination of recombinant glycosylated proteins and peptides in biological fluids
US20060194954A1 (en) * 1998-04-02 2006-08-31 Genentech, Inc. Polypeptide variants
US20030158389A1 (en) * 1998-04-02 2003-08-21 Genentech, Inc. Polypeptide variants
US20030166868A1 (en) * 1998-04-02 2003-09-04 Genentech, Inc. Polypeptide variants
US7741072B2 (en) 1998-04-02 2010-06-22 Genentech, Inc. Polypeptide variants
US7364731B2 (en) 1998-04-02 2008-04-29 Genentech, Inc. Polypeptide variants
US7297775B2 (en) 1998-04-02 2007-11-20 Genentech, Inc. Polypeptide variants
US7332581B2 (en) 1999-01-15 2008-02-19 Genentech, Inc. Polypeptide variants with altered effector function
US20050233382A1 (en) * 1999-01-15 2005-10-20 Genentech, Inc. Polypeptide variants with altered effector function
US8674083B2 (en) 1999-01-15 2014-03-18 Genentech, Inc. Polypeptide variants with altered effector function
US20060194291A1 (en) * 1999-01-15 2006-08-31 Genentech, Inc. Polypeptide variants with altered effector function
US20060194957A1 (en) * 1999-01-15 2006-08-31 Genentech, Inc. Polypeptide variants with altered effector function
US20050118174A1 (en) * 1999-01-15 2005-06-02 Genentech, Inc. Polypeptide variants with altered effector function
US20060194290A1 (en) * 1999-01-15 2006-08-31 Genentech, Inc. Polypeptide variants with altered effector function
US7122637B2 (en) 1999-01-15 2006-10-17 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US20040191244A1 (en) * 1999-01-15 2004-09-30 Genentech, Inc. Polypeptide variants with altered effector function
US8163882B2 (en) 1999-01-15 2012-04-24 Genentech, Inc. Polypeptide variants with altered effector function
US7790858B2 (en) 1999-01-15 2010-09-07 Genentech, Inc. Polypeptide variants with altered effector function
US7335742B2 (en) 1999-01-15 2008-02-26 Genentech, Inc. Polypeptide variants with altered effector function
US20040228856A1 (en) * 1999-01-15 2004-11-18 Genentech, Inc. Polypeptide variants with altered effector function
US7371826B2 (en) 1999-01-15 2008-05-13 Genentech, Inc. Polypeptide variants with altered effector function
US7416727B2 (en) 1999-01-15 2008-08-26 Genentech, Inc. Polypeptide variants with altered effector function
US20080274506A1 (en) * 1999-01-15 2008-11-06 Genentech, Inc. Polypeptide variants with altered effector function
US20080274105A1 (en) * 1999-01-15 2008-11-06 Genentech, Inc. Polypeptide variants with altered effector function
US20080274108A1 (en) * 1999-01-15 2008-11-06 Genentech, Inc. Polypeptide variants with altered effector function
US7785791B2 (en) 1999-01-15 2010-08-31 Genentech, Inc. Polypeptide variants with altered effector function
US7270964B2 (en) 2000-05-18 2007-09-18 United States Of America As Represented By The Secretary Of The Army Detection of antibodies to squalene in serum
US20060160160A1 (en) * 2000-05-18 2006-07-20 Alving Carl R Detection of human antibodies to squalene in serum
US20040248224A1 (en) * 2000-05-18 2004-12-09 Alving Carl R. Detection of antibodies to squalene in serum
US7824864B2 (en) 2000-05-18 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Detection of human antibodies to squalene in serum
US20050080239A1 (en) * 2001-04-06 2005-04-14 The Scripps Research Institute Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
US20100255013A1 (en) * 2001-10-25 2010-10-07 Presta Leonard G Glycoprotein compositions
US20110086050A1 (en) * 2001-10-25 2011-04-14 Presta Leonard G Glycoprotein compositions
US8278065B2 (en) 2008-06-30 2012-10-02 Morphotek, Inc. Polynucleotides encoding anti-GD2 antibodies
US8507657B2 (en) 2008-06-30 2013-08-13 Morphotek, Inc. Anti-GD2 antibodies
US20100008851A1 (en) * 2008-06-30 2010-01-14 Morphotek Inc, Anti-gd2 antibodies and methods and uses related thereto
US8956832B2 (en) 2008-06-30 2015-02-17 Morphotek, Inc. Cells expressing anti-GD2 antibodies and methods related thereto
US8969526B2 (en) 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US10683345B2 (en) 2012-07-13 2020-06-16 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US12503503B2 (en) 2018-10-29 2025-12-23 Hoffmann-La Roche Inc. Bispecific anti-VEGF/ANG2 antibody formulation

Also Published As

Publication number Publication date
PT687295E (pt) 2004-04-30
JP4796682B2 (ja) 2011-10-19
DE69433378T2 (de) 2004-10-14
AU6238094A (en) 1994-09-14
ATE255633T1 (de) 2003-12-15
CA2156857A1 (en) 1994-09-01
EP0687295B1 (en) 2003-12-03
JPH08507209A (ja) 1996-08-06
EP0687295A4 (en) 1997-01-15
WO1994019457A1 (en) 1994-09-01
CA2156857C (en) 2006-05-09
JP2011209287A (ja) 2011-10-20
DK0687295T3 (da) 2004-04-05
EP0687295A1 (en) 1995-12-20
ES2211877T3 (es) 2004-07-16
DE69433378D1 (de) 2004-01-15
AU687791B2 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
US5419904A (en) Human B-lymphoblastoid cell line secreting anti-ganglioside antibody
US5208146A (en) Murine monoclonal anti-idiotype antibodies
Herlyn et al. Anti-idiotypic antibodies bear the internal image of a human tumor antigen
Robbins et al. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line
KR930003912B1 (ko) 모노클로날 항체 및 제조방법
CA2209172C (en) Murine monoclonal anti-idiotype antibody 3h1
AU768002B2 (en) Immunotherapeutic composition and method for the treatment of prostate cancer
US5653977A (en) Anti-idiotypic antibody that mimics the GD2 antigen
Yamaguchi et al. Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient.
EP0657471A1 (en) Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours
Sen et al. Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2
US5493009A (en) Antiidiotypic monoclonal antibodies MK2-23 anti-melanomal antibody 763.74
Herlyn et al. Anti-idiotypic antibodies in cancer therapy
US5780029A (en) Antidiotypic monoclonal antibodies for treatment of melanoma
US5858361A (en) Monoclonal anti-idiotypic anti-CA125 antibodies and pharmaceutical compositions containing them
US6042827A (en) Anti-idiotypic antibody induction of anti-tumor response
WO1993010221A1 (en) Chimeric murine/human anti-idiotype monoclonal antibodies
EP0428485A1 (en) Novel antiidiotypic monoclonal antibodies
Saito et al. Murine monoclonal anti-idiotype antibody (α) as a probe to detect human monoclonal antibody bound to human tumor tissues
Warren et al. Induction of immunity to a human osteosarcoma-associated antigen in mice using anti-idiotypic antibodies
Janson et al. Three Kinds of Tumour‐Unique Surface Molecules on a Human T‐Cell Chronic Lymphocytic Leukaemia (T‐CLL) Detected by Monoclonal Antibodies
WO1997040140A1 (en) Gd2 anti-idiotypic antibodies and uses thereof
JP2001520034A (ja) 抗イディオタイプモノクローナル抗体、悪性腫瘍の能動免疫療法におけるそれらの使用、およびそれらを含有する組成物
Taylor-Papadimitriou et al. Development of monoclonal antibodies with specificity for human epithelial cells
O'Connell Molecular characterization by mRNA sequencing of Ab1, Ab2 and Ab1'/Ab3 syngeneic murine monoclonal antibodies in an idiotypic cascade elicited by the human high molecular weight-melanoma associated antigen

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF CALIFORNIA;REEL/FRAME:026319/0792

Effective date: 19940705